Fallon Marie E. 的 Form 4 申報
Ginkgo Bioworks Holdings, Inc.（DNA），2023/1/6 申報
- 申報編號
- 0001127602-23-001108
- 申報時間
- 2023/1/6
- 交易日
- 2023/1/3-1/4
- 申報延遲
- 3 天遲報
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 3 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $1.23 萬。交易後 3 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Fallon Marie E.CIK 0001883686 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。
- F3
Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。
備註
Chief Accounting Officer